Delivery Order SPE2DB25D3003-SPE2DB25FPWZK
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,532.33 on August 27, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This firm fixed-price, competitively awarded contract is set to be completed by August 28, 2025, and will be performed at the awardee's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management and diabetes treatment, reflecting the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $42,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,963.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on August 7, 2025, with completion expected by August 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management and represents part of the...
- The Defense Logistics Agency awarded a delivery order valued at $8,512.52 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This firm fixed-price, non-competitive set-aside delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing part of the federal government's pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,086.13 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pens on August 8, 2025, with a completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $3,134.95 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pens on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitive, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $11,574.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on April 24, 2025, with an ultimate completion date of April 25, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a $13,150.18 delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen injectors on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $17,888.06 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 6, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in weight management therapy, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $20,840.52 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injections on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management treatment,...
- SPE2DB25D3003Indefinite Delivery Contract
- SPE2DB25D3003-SPE2DB25FPWZKDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,758.58 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication primarily indicated for weight management in adults with obesity or overweight conditions, representing part of the federal government's pharmaceutical procurement needs for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive pharmaceutical support vehicle running through December 2026. The IDC serves as a global procurement vehicle enabling AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The company, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant federal contract portfolio with DLA focused on delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 8/19/25 |